3 Cases ➡️ The therapeutic potential of sequential use of ADC containing the same chemotherapeutic reagents with different targets for metastatic urothelial cancer.

🔓journals.sagepub.com/share/DUJJCIRFYH7VFMXEDN...

#bladdercancer #CanSky #OncoSky

BCAN Summit 2026! #bladdercancer #bladdercancerwarrior #advocacy #bcan

Smartwatches coming of age Volume 13, Issue 10 | March 12, 2026

ALSO IN THIS ISSUE

A blood test that could let you keep your bladder
To diagnose disease, could we just follow the energy?

open.substack.com/pub/sensitiv...

#sensitiveandspecific #diagnostics #smartwatch #wearabledevice #healthmonitoring #healthscreening #afib #hypertension #bladdercancer

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRRj7w !

#Oncology #SocialListening #LucidQuest

HealtheVoices Advisory Panel 2026! #bladdercancer #bladdercancerwarrior #advocacy #johnsonandjohnson #healthevoices

Management of high-risk NMIBC is evolving beyond BCG alone.

Get practical insights on immunotherapy plus BCG, including key clinical evidence and strategies for managing patients in everyday practice.

👉 Access the program: bit.ly/3MT4yKg

#NMIBC #BladderCancer #Urology

The cover of The Lancet Primary Care February 2026 issue, featuring a pharmacist helping an older patient with their prescription.

Our new issue is out now 🎉

We feature research on #bladdercancer, routine testing for detection of #syphilis, and point-of-care testing strategies for #antibioticprescribing for respiratory tract infections, and more!

Explore and download the issue on our journal homepage: hubs.li/Q03yqV6c0.

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial

Dr Galsky on the Design of the KEYNOTE-B15 Trial in MIBC | OncLive Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.

📹 @mattgalsky.bsky.social of @mountsinainyc.bsky.social unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC. #oncology #medtwitter #MIBC #bladdercancer
Watch here: www.onclive.com/view/dr-gals...

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab Discover the two conceptually distinct paradigms that could transform the neoadjuvant treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer, and understand how they might be…

Discover the two conceptually distinct paradigms that could transform the neoadjuvant treatment of #cisplatin-ineligible patients with muscle-invasive #BladderCancer, and understand how they might be selected and sequenced.

👉 buff.ly/KzE5jri

#OncSky

The ABC UK ‘Nursing Grants Programme’ is a grant of up to £10,000 specifically for specialist nurses to support small, nurse-led, projects for the improvement of both patient experience and their treatment pathway.

Find out more: actionbladdercanceruk.org/research/

#Research #BladderCancer

NICE Technology Appraisal Guideline [TA1138]: Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive #BladderCancer. www.nice.org.uk/guidance/ta1...

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study Perioperative sacituzumab govitecan plus pembrolizumab revealed a promising clinical complete response rate, without the occurrence of grade 4 or higher adverse events, allowing a bladder preservation...

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive #BladderCancer (SURE-02): a single-arm, phase 2 study. www.thelancet.com/journals/lan...

Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸

We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of:

Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905 #BladderCancer

Yesterday Di, represented #ABCUK at the The Royal Marsden NHS Foundation Trust study day on systemic treatments for prostate, bladder & kidney cancer.

She’ll also be at the 30 April event: Fundamentals of Bladder Cancer for Nurses & AHPs.

#BladderCancer #PatientSupport

Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case–control study Our data suggest that recurrent UTIs within 6 months were a strong signal of bladder cancer risk. Our findings can help to refine existing guideline recommendations for patients with recurrent UTIs wh...

... 🆕 In their Article, Sikhuphukile G Mahati and colleagues aimed to better define and quantify the effect of recurrent urinary tract infections on the likelihood of #bladdercancer

Read the full Article ➡️ www.thelancet.com/journals/lan...
@jianhuawu6.bsky.social
#UTI #primarycare #medsky

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRGBBY !

#Oncology #SocialListening #LucidQuest

Have a project that could improve bladder cancer outcomes or support patients? Apply for funding of up to £10,000. Applications are open until 30 March 2026.

Find out more, here: actionbladdercanceruk.org/research/

#ResearchFunding #CancerResearch #CancerFunding #BladderCancer

At @ascocancer.bsky.social #GU26, results from @swog.org S1602 ph 3 trial to evaluate BCG strain differences & intradermal BCG priming in high-grade NMIBC:
finds Tokyo BCG is non-inferior to TICE BCG & could mitigate BCG shortage. #BladderCancer
In UroToday at
www.urotoday.com/conference-h...

For clinicians treating NMIBC, tolerability drives success with intravesical therapy.

Get practical tips to prevent early AEs, manage challenges, and improve procedural technique.

👉 Access the program: bit.ly/46CiLlk

#HCPEducation #NMIBC #BladderCancer #Urology #Oncology

Kicking off Day 2 of #USANZ26, the #bladdercancer Breakfast Symposium with presentations by Anthony Ta and Alysson Wann. The session considers recent advances in NMIBC, MIBC and adjuvant therapy. The session is sponsored by @astrazeneca.bsky.social

Dr. Bellmunt concludes IMvigor011:

🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk

💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS

#GU26 #BladderCancer #MIBC

🔬 Dr. Bellmunt presents IMvigor011: early ctDNA positivity after RC was frequent and typically detected within <24 wks

📉Baseline ctDNA levels differed by risk group, and ctDNA kinetics showed clear divergence between arms over time

#GU26 #BladderCancer #MIBC #Oncology

Can ctDNA timing and dynamics refine adjuvant treatment decisions in #MIBC?
Follow our #GU26 coverage for new insights from Joaquim Bellmunt on the IMvigor011 trial

#BladderCancer #Oncology #MedSky #MedEd

Matthew D. Galsky concludes neoadjuvant + adjuvant EV+pembro improved EFS, OS and pCR vs cis+gem in cisplatin‑eligible MIBC 📈

Efficacy appeared consistent across subgroups and no new safety signals were seen

Findings support EV+pembro as a novel option in MIBC

#GU26 #BladderCancer

New research from #GU26 to share with your #BladderCancer patients: Combining enfortumab vedotin with pembrolizumab before and after surgery can help reduce risk of recurrence for some people with #MIBC.

Learn more: https://bit.ly/4rBsOzC

We’re back with more #GU26 coverage!
Today we kick-off with the latest results from the KEYNOTE-B15 study presented by Matthew D. Galsky

#BladderCancer #Oncology #MIBC #MedEd #MedSky

The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/u2B4SNk

Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer

The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26
Presentation by Dr. Tom Powles: Year in Review in #BladderCancer
REGISTER HERE TO WATCH: buff.ly/pKfMiwK

Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT) Patients with locally advanced bladder cancer have a poor prognosis despite radical surgery. Early data on neoadjuvant immunotherapy are promising, wi…

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced #BladderCancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). www.sciencedirect.com/science/arti...